Lonza (LONN.SW)

Executive Summary

Lonza Group AG is the world's leading Contract Development and Manufacturing Organization (CDMO), providing end-to-end solutions across biologics, cell and gene therapies, and small molecules. The company has faced headwinds in 2023-2024 due to post-pandemic demand normalization and customer inventory destocking, but its diversified platform and strong relationships with top pharma and biotech clients position it for recovery. Under new CEO Wolfgang Wienand, Lonza is executing a strategic transformation focused on operational efficiency, innovation, and high-growth modalities like ADCs and mRNA. As biotech funding rebounds and outsourcing trends persist, Lonza is poised to return to growth. The company's robust pipeline of over 400 programs and recent capacity expansions in Switzerland and the US underpin its competitive advantage. Long-term, Lonza is expected to benefit from increasing drug complexity and demand for specialized manufacturing services.

Upcoming Catalysts (preview)

• H2 2026Spin-off of Bioscience Division80% success
• Q3 2026Major CDMO Contract Win with Top 10 Pharma65% success
• H1 2026FDA Approval for Drug Manufactured by Lonza (e.g., CRISPR Therapy)70% success